Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Central Pharmaceutical JSC No. 3 should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
1.60%
EBIT Growth (5y)
7.37%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.64
Sales to Capital Employed (avg)
0.88
Tax Ratio
20.24%
Dividend Payout Ratio
53.23%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
68.54%
ROE (avg)
26.75%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
2.20
EV to EBIT
5.18
EV to EBITDA
4.90
EV to Capital Employed
5.90
EV to Sales
1.85
PEG Ratio
1.28
Dividend Yield
5.75%
ROCE (Latest)
113.87%
ROE (Latest)
24.96%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -0.29% (YoY
CASH AND EQV(HY)
Highest at VND 771,561.25 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -75.51 %
-11What is not working for the Company
INTEREST(Q)
At VND 296.06 MM has Grown at 356.87%
INTEREST COVERAGE RATIO(Q)
Lowest at 10,874.59
DEBTORS TURNOVER RATIO(HY)
Lowest at 9.05%
NET SALES(Q)
At VND 94,243.65 MM has Fallen at -7.09%
Here's what is working for Central Pharmaceutical JSC No. 3
Cash and Eqv
Highest at VND 771,561.25 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -75.51 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -0.29% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Central Pharmaceutical JSC No. 3
Interest
At VND 296.06 MM has Grown at 356.87%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (VND MM)
Interest Coverage Ratio
Lowest at 10,874.59
in the last five periodsMOJO Watch
The company's ability to manage interest payments is deteriorating
Operating Profit to Interest
Net Sales
At VND 94,243.65 MM has Fallen at -7.09%
over average net sales of the previous four periods of VND 101,433.32 MMMOJO Watch
Near term sales trend is negative
Net Sales (VND MM)
Interest
Highest at VND 296.06 MM
in the last five periods and Increased by 356.87% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (VND MM)
Debtors Turnover Ratio
Lowest at 9.05%
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Non Operating Income
Highest at VND 0.22 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
